Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

Shona C Moore,Barbara Kronsteiner,Stephanie Longet,Sandra Adele,Alexandra S Deeks,Chang Liu,Wanwisa Dejnirattisai,Laura Silva Reyes,Naomi Meardon,Sian Faustini,Saly Al-Taei,Tom Tipton,Luisa M Hering,Adrienn Angyal,Rebecca Brown,Alexander R Nicols,Susan L Dobson,Piyada Supasa,Aekkachai Tuekprakhon,Andrew Cross,Jessica K Tyerman,Hailey Hornsby,Irina Grouneva,Megan Plowright,Peijun Zhang,Thomas A H Newman,Jeremy M Nell,Priyanka Abraham,Mohammad Ali,Tom Malone,Isabel Neale,Eloise Phillips,Joseph D Wilson,Sam M Murray,Martha Zewdie,Adrian Shields,Emily C Horner,Lucy H Booth,Lizzie Stafford,Sagida Bibi,Daniel G Wootton,Alexander J Mentzer,Christopher P Conlon,Katie Jeffery,Philippa C Matthews,Andrew J Pollard,Anthony Brown,Sarah L Rowland-Jones,Juthathip Mongkolsapaya,Rebecca P Payne,Christina Dold,Teresa Lambe,James E D Thaventhiran,Gavin Screaton,Eleanor Barnes,Susan Hopkins,Victoria Hall,Christopher J A Duncan,Alex Richter,Miles Carroll,Thushan I de Silva,Paul Klenerman,Susanna Dunachie,Lance Turtle,PITCH Consortium

DOI: https://doi.org/10.1016/j.medj.2023.02.004

2023-03-10

Med

Abstract:Background: Both infection and vaccination, alone or in combination, generate antibody and T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the maintenance of such responses-and hence protection from disease-requires careful characterization. In a large prospective study of UK healthcare workers (HCWs) (Protective Immunity from T Cells in Healthcare Workers [PITCH], within the larger SARS-CoV-2 Immunity and Reinfection Evaluation [SIREN] study), we previously observed that prior infection strongly affected subsequent cellular and humoral immunity induced after long and short dosing intervals of BNT162b2 (Pfizer/BioNTech) vaccination. Methods: Here, we report longer follow-up of 684 HCWs in this cohort over 6-9 months following two doses of BNT162b2 or AZD1222 (Oxford/AstraZeneca) vaccination and up to 6 months following a subsequent mRNA booster vaccination. Findings: We make three observations: first, the dynamics of humoral and cellular responses differ; binding and neutralizing antibodies declined, whereas T and memory B cell responses were maintained after the second vaccine dose. Second, vaccine boosting restored immunoglobulin (Ig) G levels; broadened neutralizing activity against variants of concern, including Omicron BA.1, BA.2, and BA.5; and boosted T cell responses above the 6-month level after dose 2. Third, prior infection maintained its impact driving larger and broader T cell responses compared with never-infected people, a feature maintained until 6 months after the third dose. Conclusions: Broadly cross-reactive T cell responses are well maintained over time-especially in those with combined vaccine and infection-induced immunity ("hybrid" immunity)-and may contribute to continued protection against severe disease. Funding: Department for Health and Social Care, Medical Research Council.